脑炎症治疗后痴呆综合征的恢复。

IF 1.4 Q4 CLINICAL NEUROLOGY Dementia and Geriatric Cognitive Disorders Extra Pub Date : 2020-01-21 eCollection Date: 2020-01-01 DOI:10.1159/000504880
Jong-Hoon Lee, Su-Hee Choi, Chul Joong Lee, Sang-Suk Oh
{"title":"脑炎症治疗后痴呆综合征的恢复。","authors":"Jong-Hoon Lee,&nbsp;Su-Hee Choi,&nbsp;Chul Joong Lee,&nbsp;Sang-Suk Oh","doi":"10.1159/000504880","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim/background: </strong>This research aims to prevent progression from mild cognitive impairment (MCI) to Alzheimer's disease. A Japanese study of leprosy patients revealed that the incidence of dementia in leprosy patients was lower than that in patients taking dapsone who had never been treated. But a similar study the following year refuted the finding of less dementia in leprosy patients taking dapsone. According to conflicting reports, <i>Mycobacterium leprae</i> was a factor in reducing the incidence of Alzheimer's disease. Thus, we formed a hypothesis that if dapsone is administered to patients without leprosy but with MCI and the prophylactic effect of dementia syndrome is observed over a long period of time, we can determine whether dapsone can prevent the progression of MCI to dementia syndrome. If dementia does not occur after treating inflammation in brain cells while dementia develops after a certain long-term period (usually within 2-3 years), brain cell inflammation can be demonstrated as the cause of dementia.</p><p><strong>Methods: </strong>This is a prospective cohort research. We report on an elderly patient diagnosed with MCI from February 2008 to January 2019. The patient took dapsone 100 mg once a day from 2010 to 2015 for the treatment of MCI. Since 2016, the production of dapsone has ceased in Korea. In June 2018, the patient was diagnosed with Alzheimer's disease. The patient took Aricept for the treatment of Alzheimer's disease but complained of serious side effects. And dapsone was re-administered to the patient from November 2018.</p><p><strong>Results: </strong>The patient recovered to MCI and improved her daily life owing to the treatment with dapsone. The drug controls the inflammatory response in the brain, irrespective of whether proteins are deposited in neurons.</p><p><strong>Conclusions: </strong>This finding means that dementia syndrome is an inflammatory disease. This research suggests that diagnostic criteria for Alzheimer's disease should be based on the presence or absence of inflammation in neurons. Because inflammation in neurons can occur in middle age due to various causes, we can treat inflammation in neurons and prevent and treat dementia syndrome, including Alzheimer's disease.</p>","PeriodicalId":38017,"journal":{"name":"Dementia and Geriatric Cognitive Disorders Extra","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2020-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000504880","citationCount":"26","resultStr":"{\"title\":\"Recovery of Dementia Syndrome following Treatment of Brain Inflammation.\",\"authors\":\"Jong-Hoon Lee,&nbsp;Su-Hee Choi,&nbsp;Chul Joong Lee,&nbsp;Sang-Suk Oh\",\"doi\":\"10.1159/000504880\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim/background: </strong>This research aims to prevent progression from mild cognitive impairment (MCI) to Alzheimer's disease. A Japanese study of leprosy patients revealed that the incidence of dementia in leprosy patients was lower than that in patients taking dapsone who had never been treated. But a similar study the following year refuted the finding of less dementia in leprosy patients taking dapsone. According to conflicting reports, <i>Mycobacterium leprae</i> was a factor in reducing the incidence of Alzheimer's disease. Thus, we formed a hypothesis that if dapsone is administered to patients without leprosy but with MCI and the prophylactic effect of dementia syndrome is observed over a long period of time, we can determine whether dapsone can prevent the progression of MCI to dementia syndrome. If dementia does not occur after treating inflammation in brain cells while dementia develops after a certain long-term period (usually within 2-3 years), brain cell inflammation can be demonstrated as the cause of dementia.</p><p><strong>Methods: </strong>This is a prospective cohort research. We report on an elderly patient diagnosed with MCI from February 2008 to January 2019. The patient took dapsone 100 mg once a day from 2010 to 2015 for the treatment of MCI. Since 2016, the production of dapsone has ceased in Korea. In June 2018, the patient was diagnosed with Alzheimer's disease. The patient took Aricept for the treatment of Alzheimer's disease but complained of serious side effects. And dapsone was re-administered to the patient from November 2018.</p><p><strong>Results: </strong>The patient recovered to MCI and improved her daily life owing to the treatment with dapsone. The drug controls the inflammatory response in the brain, irrespective of whether proteins are deposited in neurons.</p><p><strong>Conclusions: </strong>This finding means that dementia syndrome is an inflammatory disease. This research suggests that diagnostic criteria for Alzheimer's disease should be based on the presence or absence of inflammation in neurons. Because inflammation in neurons can occur in middle age due to various causes, we can treat inflammation in neurons and prevent and treat dementia syndrome, including Alzheimer's disease.</p>\",\"PeriodicalId\":38017,\"journal\":{\"name\":\"Dementia and Geriatric Cognitive Disorders Extra\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2020-01-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1159/000504880\",\"citationCount\":\"26\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dementia and Geriatric Cognitive Disorders Extra\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000504880\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dementia and Geriatric Cognitive Disorders Extra","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000504880","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 26

摘要

目的/背景:本研究旨在预防轻度认知障碍(MCI)发展为阿尔茨海默病。日本一项对麻风病患者的研究显示,麻风病患者痴呆的发生率低于从未接受过治疗的服用氨苯砜的患者。但次年的一项类似研究驳斥了麻风病患者服用氨苯砜后痴呆减少的说法。根据相互矛盾的报道,麻风分枝杆菌是降低阿尔茨海默病发病率的一个因素。因此,我们形成了一个假设,如果对没有麻风但患有MCI的患者给予氨苯砜,并长期观察其对痴呆综合征的预防作用,我们可以确定氨苯砜是否可以预防MCI向痴呆综合征的进展。如果在治疗脑细胞炎症后没有发生痴呆,而痴呆在一定的时间(通常在2-3年内)后发生,则可以证明脑细胞炎症是痴呆的原因。方法:前瞻性队列研究。我们报告了2008年2月至2019年1月诊断为轻度认知障碍的一位老年患者。患者于2010 - 2015年服用氨苯砜100 mg,每日1次,治疗轻度认知损伤。从2016年开始,韩国停止了氨苯砜的生产。2018年6月,该患者被诊断患有阿尔茨海默病。患者服用阿立赛普治疗阿尔茨海默病,但抱怨有严重的副作用。从2018年11月开始,患者再次服用氨苯砜。结果:患者经氨苯砜治疗后恢复为轻度认知损伤,日常生活得到改善。这种药物可以控制大脑的炎症反应,而不管蛋白质是否沉积在神经元中。结论:这一发现意味着痴呆综合征是一种炎症性疾病。这项研究表明,阿尔茨海默病的诊断标准应该基于神经元炎症的存在或不存在。由于各种原因,神经元炎症会在中年发生,因此可以治疗神经元炎症,预防和治疗阿尔茨海默病等痴呆综合征。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Recovery of Dementia Syndrome following Treatment of Brain Inflammation.

Aim/background: This research aims to prevent progression from mild cognitive impairment (MCI) to Alzheimer's disease. A Japanese study of leprosy patients revealed that the incidence of dementia in leprosy patients was lower than that in patients taking dapsone who had never been treated. But a similar study the following year refuted the finding of less dementia in leprosy patients taking dapsone. According to conflicting reports, Mycobacterium leprae was a factor in reducing the incidence of Alzheimer's disease. Thus, we formed a hypothesis that if dapsone is administered to patients without leprosy but with MCI and the prophylactic effect of dementia syndrome is observed over a long period of time, we can determine whether dapsone can prevent the progression of MCI to dementia syndrome. If dementia does not occur after treating inflammation in brain cells while dementia develops after a certain long-term period (usually within 2-3 years), brain cell inflammation can be demonstrated as the cause of dementia.

Methods: This is a prospective cohort research. We report on an elderly patient diagnosed with MCI from February 2008 to January 2019. The patient took dapsone 100 mg once a day from 2010 to 2015 for the treatment of MCI. Since 2016, the production of dapsone has ceased in Korea. In June 2018, the patient was diagnosed with Alzheimer's disease. The patient took Aricept for the treatment of Alzheimer's disease but complained of serious side effects. And dapsone was re-administered to the patient from November 2018.

Results: The patient recovered to MCI and improved her daily life owing to the treatment with dapsone. The drug controls the inflammatory response in the brain, irrespective of whether proteins are deposited in neurons.

Conclusions: This finding means that dementia syndrome is an inflammatory disease. This research suggests that diagnostic criteria for Alzheimer's disease should be based on the presence or absence of inflammation in neurons. Because inflammation in neurons can occur in middle age due to various causes, we can treat inflammation in neurons and prevent and treat dementia syndrome, including Alzheimer's disease.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Dementia and Geriatric Cognitive Disorders Extra
Dementia and Geriatric Cognitive Disorders Extra Medicine-Psychiatry and Mental Health
CiteScore
4.30
自引率
0.00%
发文量
18
审稿时长
9 weeks
期刊介绍: This open access and online-only journal publishes original articles covering the entire spectrum of cognitive dysfunction such as Alzheimer’s and Parkinson’s disease, Huntington’s chorea and other neurodegenerative diseases. The journal draws from diverse related research disciplines such as psychogeriatrics, neuropsychology, clinical neurology, morphology, physiology, genetic molecular biology, pathology, biochemistry, immunology, pharmacology and pharmaceutics. Strong emphasis is placed on the publication of research findings from animal studies which are complemented by clinical and therapeutic experience to give an overall appreciation of the field. Dementia and Geriatric Cognitive Disorders Extra provides additional contents based on reviewed and accepted submissions to the main journal Dementia and Geriatric Cognitive Disorders Extra .
期刊最新文献
Fear of Dementia among Middle-Aged and Older Adults in Germany. Characteristics of Alzheimer's Disease and Mild Cognitive Impairment Influenced by the Time of Onset. Prevalence of Geriatric Syndromes among Older Outpatients with Dementia. Criterion-Related Validity of the Cognitive Function Score with the Revised Hasegawa's Dementia Scale and the Bedriddenness Rank with the Barthel Index and the Katz Index: A Multi-Center Retrospective Study. What’s new in dementia risk prediction modelling? An updated systematic review
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1